Daily Stock Analysis, ALDX, Aldeyra Therapeutics Inc, priceseries

Aldeyra Therapeutics Inc. Daily Stock Analysis
Stock Information
Open
5.79
Close
5.92
High
6.10
Low
5.76
Previous Close
5.76
Daily Price Gain
0.16
YTD High
12.79
YTD High Date
Mar 26, 2019
YTD Low
4.31
YTD Low Date
Aug 30, 2019
YTD Price Change
-2.59
YTD Gain
-30.43%
52 Week High
16.70
52 Week High Date
Sep 26, 2018
52 Week Low
4.31
52 Week Low Date
Aug 30, 2019
52 Week Price Change
-3.18
52 Week Gain
-34.95%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
May 15. 2017
4.15
Jun 9. 2017
4.96
18 Trading Days
19.47%
Link
LONG
Sep 13. 2017
6.35
Sep 19. 2017
7.04
4 Trading Days
10.83%
Link
LONG
Apr 25. 2018
7.20
May 10. 2018
7.84
11 Trading Days
8.86%
Link
LONG
Sep 19. 2018
8.05
Oct 10. 2018
12.00
15 Trading Days
49.11%
Link
LONG
Dec 31. 2018
8.30
Jan 14. 2019
8.96
9 Trading Days
7.91%
Link
LONG
Aug 7. 2019
5.44
Aug 8. 2019
5.72
1 Trading Days
5.15%
Link
Company Information
Stock Symbol
ALDX
Exchange
NasdaqCM
Company URL
http://www.aldeyra.com
Company Phone
781-761-4904
CEO
Todd C. Brady
Headquarters
Massachusetts
Business Address
131 HARTWELL AVENUE, SUITE 320, LEXINGTON, MA 02421
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001341235
About

Aldeyra Therapeutics, Inc. operates as a biotechnology company. It primarily focuses on the development of new products for immune-mediated, inflammatory, orphan and other diseases that are thought to be caused in part by naturally occurring toxic chemical species known as free aldehydes. The company was founded by Thomas A. Jordan and John E. Dowling on August 13, 2004 and is headquartered in Lexington, MA.

Description

Aldeyra Therapeutics, Inc., a biotechnology company, focuses on the development of products for diseases caused by inflammation and inborn errors of metabolism in the United States and internationally. It is developing NS2, a small molecule designed to trap and allow for the degradation of aldehydes. Its product is used for the treatment of allergic conjunctivitis, noninfectious anterior uveitis, sjogren-larsson syndrome, and succinic semi-aldehyde dehydrogenase deficiency. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was founded in 2004 and is based in Lexington, Massachusetts.